Percutaneous coronary interventions to the proximal left anterior descending artery (pLAD)-acute myocardial infarction (AMI) are still challenging, especially in the ostial pLAD. Clinical outcomes of the ostial pLAD-AMI were not well investigated. The aim of the present study was to compare clinical outcomes of the ostial pLAD-AMI with those of the non-ostial pLAD-AMI. The primary endpoint was the major cardiovascular events (MACE), defined as the composite of cardiac death, AMI, stent thrombosis (ST), target lesion revascularization (TLR), and target vessel revascularization (TVR). Between January 2009 and March 2016, a total of 401 pLAD-AMI were included as the study population and were divided into 78 ostial pLAD-AMI (the ostial pLAD group), and 323 non-ostial pLAD-AMI (the non-ostial pLAD group). The median follow-up duration was 414 days. The MACE tended to be higher in the ostial pLAD group (8.0% at 30 days, 19.9% at 400 days) than in the non-ostial pLAD group (4.4% at 30 days, 12.9% at 400 days) without reaching statistical significance (P = 0.087). The prevalence of cardiac death was significantly higher in the ostial pLAD group (6.6% at 30 days, 9.5% at 400 days) as compared with the non-ostial pLAD group (3.1% at 30 days, 4.5% at 400 days) (P = 0.034). There were no significant differences in ST, AMI, TLR, or TVR. We concluded that, as compared with the non-ostial pLAD-AMI, the clinical outcomes of the ostial pLAD-AMI, especially cardiac death, tended to be worse, requiring special attention to the ostial pLAD-AMI.
T he development of devices and procedure has improved clinical outcomes of percutaneous coronary intervention (PCI) to the culprit of acute myocardial infarction (AMI). [1] [2] [3] However, proximal left anterior descending artery (LAD)-AMI has still been associated with high morbidity and mortality because of the broad ischemic area. 4, 5) In fact, clinical outcomes were significantly worse in the proximal LAD-AMI as compared with the mid LAD-AMI. 5) Moreover, the proximal LAD disease in stable angina was closely associated with early revascularization following optimal medical therapy. 6) Therefore, clinical guidelines regarding coronary revascularization have discriminated the proximal LAD disease from other LAD diseases. 7) In terms of coronary revascularization, the ostial LAD disease requires special attention in the proximal LAD disease, because percutaneous coronary interventions (PCI) can be more complex in the ostial LAD disease than in the non-ostial proximal LAD disease. 8) Even in the setting of AMI, left-main-trunk (LMT)-to-LAD crossover stenting was frequently required in the ostial LAD disease. 9) However, the direct comparison in clinical outcomes between the ostial proximal LAD (pLAD)-AMI and the non-ostial pLAD-AMI has not been discussed in the literature. We hypothesized that clinical outcomes of the ostial pLAD-AMI would be worse as compared with the non-ostial pLAD-AMI. The purpose of the present study was to compare mid-term clinical outcomes between the ostial pLAD-AMI and the non-ostial pLAD-AMI.
Methods
Study design: The present study was a retrospective and single center study. We included AMI patients whose culprits were pLAD between January 2009 and March 2016. The pLAD-AMI patients were divided into the ostial pLAD group and the non-ostial but proximal group (the non-ostial pLAD group). The pLAD lesion was defined as the lesion on or before the first major septal perforator branch. 10) An ostial lesion was defined as a narrowing located within 3 mm of the vessel origin in the least foreshortened angiographic projection.
11) The difference be-YAMAMOTO, ET AL tween the ostial pLAD group and non-ostial pLAD group is described in Figure 1 . We excluded patients who underwent coronary artery bypass grafting for AMI. The primary endpoint was the major cardiovascular events (MACE) defined as being the composite of cardiac death, AMI, stent thrombosis (ST), target lesion revascularization (TLR), and target vessel revascularization (TVR). Clinical outcomes were acquired from hospital records. This study was approved by the institutional review board and written informed consent was waived, owing to the retrospective study design. Definitions: In the present study, AMI was defined as persistent chest pain, elevation of cardiac enzyme (at least two-fold increases from normal upper limit), and STsegment elevation or depression in electrocardiograms. 4, 12, 13) A definite ST by ARC definition was included as ST. 14) Hypertension was defined as systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg, or medical treatment for hypertension. Diabetes mellitus was defined as a hemoglobin A1c level > 6.5% or treatment for diabetes mellitus. Hyperlipidemia was defined as a total cholesterol level > 220 mg/dL, a low-density lipoprotein cholesterol level > 140 mg/dL, or treatment for hyperlipidemia. Chronic kidney disease was defined as estimate glomerular filtration rate (eGFD) < 60 mL/minute. Percutaneous coronary interventions: Primary PCI was performed using standard techniques via radial artery, femoral artery, or, rarely, brachial artery. Firstly, we advanced a conventional guidewire across the lesion and used a small balloon or thrombus aspiration catheter. The choice of devices including type of stent was left to the discretion of each interventional cardiologist. Activated coagulation time (ACT) was maintained > 250 seconds during PCI. Statistical analysis: Data were expressed as mean ± SD or percentage. Categorical variables were presented as numbers (percentage) and were compared using the chisquare test (or Fisher's exact test for small samples). Con-OUTCOMES OF THE OSTIAL AND NON-OSTIAL LAD-AMI tinuous variables were compared using student's t-test. Incidences of MACE were constructed using the KaplanMeier method, and statistical differences between curves were assessed by the log-lank test. Multivariate cox regression analysis was applied to investigate the association between the ostial pLAD group and MACE, or that between the ostial pLAD group and cardiac death after controlling age, 15, 16) sex, 17, 18) STEMI, or NSTEMI. 19) Statistical significance was defined as a two-sided value of P < 0.05. Statistical analyses were performed using SPSS 18.0/Windows (Chicago, Illinois, USA).
Results
Between January 2009 and March 2016, a total of 439 patients were pLAD-AMI and were divided into the ostial pLAD group (n = 78) and the non-ostial pLAD group (n = 323) (Figure 2 ). The median follow-up duration was 414 days (IQR 224-1209 days).
The prevalence of catecholamine use was significantly higher in the ostial pLAD group (17.9%) than in the non-ostial pLAD group (6.8%) (P = 0.002). The frequency of IABP support was significantly higher in the ostial pLAD group (51.3%) than it was in the non-ostial pLAD group (18.3%) (P < 0.001) ( Table I ). The fre-YAMAMOTO, ET AL quency of crossover stenting and kissing balloon technique was significantly higher in the ostial pLAD group than it was in the non-ostial pLAD group (38.5% versus 8.4%, P < 0.001; 11.5% versus 2.8%, P = 0.003, respectively) (Table II) . The Kaplan-Meier curves were shown in Figure 3 . During the study period, the number of MACE was 61, and the number of cardiac deaths was 22. MACE tended to be higher in the ostial pLAD group (8.0% at 30 days, 19.9% at 400 days) than in the non-ostial pLAD group (4.4% at 30 days, 12.9% at 400 days) without it reaching statistical significance (P = 0.087). The prevalence of cardiac death was significantly higher in the ostial pLAD group (6.6% at 30 days, 9.5% at 400 days) as compared with the non-ostial pLAD group (3.1% at 30 days, 4.5% at 400 days) (P = 0.034). There were no significant differences in ST, AMI, TLR, or TVR between the two groups. The cause of cardiac death and event duration of each patient was shown in Table III . In multivariate cox regression analyses, the ostial pLAD group was not significantly associated with MACE (HR 1.635, 95% confidence interval (CI) 0.908-2.945, P = 0.102) after controlling age, sex, and STEMI/NSTEMI (Table IV) . The ostial pLAD group tended to be associated with cardiac death (HR 2.394, 95%CI 1.000-5.733, P = 0.05) after controlling age, sex, and STEMI/NSTEMI without reaching statistical significance (Table V) .
Discussion
The present study included 401 consecutive pLAD-AMI patients that were divided into 78 ostial pLAD-AMI patients and 323 non-ostial pLAD-AMI patients. Incidence of the ostial pLAD-AMI was approximately 20% in pLAD-AMI. Incidence of the MACE tended to be higher in the ostial pLAD group than it was in the non-ostial pLAD group. Incidence of cardiac death was significantly higher in the ostial pLAD group than it was in the nonostial pLAD group. While the pLAD-AMI is known to be the highest risk group in the LAD-AMI, 5, 20, 21) our results suggest that the ostial pLAD-AMI may be associated with worse clinical outcomes among pLAD-AMI. Figure 3 . Kaplan-Meier curves for major adverse cardiac events (A), cardiac death (B), stent thrombosis (C), acute myocardial infarction (AMI) (D), target lesion revascularization (TLR) (E), and target vessel revascularization (TVR) (F) between the ostial group and the non-ostial group. P-value was calculated by log rank test. MACE indicates major adverse cardiac event.
OUTCOMES OF THE OSTIAL AND NON-OSTIAL LAD-AMI
In the present study, the incidence of cardiac death was significantly higher in the ostial pLAD group than in the non-ostial pLAD group. Since the frequencies of IABP support and catecholamine use were significantly higher in the ostial pLAD group than they were in the non-ostial pLAD group, the severity of AMI at initial presentation might influence the higher incidence of cardiac death in the ostial pLAD group. Furthermore, peak CK/CK-MB was numerically greater in the ostial pLAD group than it was in the non-ostial pLAD group without reaching statistical significance, which suggested that the infarcted area might be greater in the ostial pLAD group than in the non-ostial pLAD group. The reason why the ostial pLAD-AMI has greater severity and infarcted area as compared with the non-ostial pLAD-AMI should be discussed. In right coronary artery (RCA)-AMI, clinical outcomes are similar between the proximal RCA-AMI and non-proximal RCA-AMI, 22) partially because there are no YAMAMOTO, ET AL 10) the non-ostial pLAD-AMI may not involve the first diagonal branch, whereas the ostial pLAD always involves the first diagonal branch. The infarction of the first diagonal branch would definitely significantly impact on left ventricular function. 23) Therefore, unlike the RCA-AMI, the more proximal lesion would have broader infarction area in the LAD-AMI.
Although the frequency of complex revascularization techniques such as LMT-LAD crossover stenting or kissing balloon technique was significantly greater in the ostial pLAD group than in the non-ostial pLAD group, incidences of ST, TLR, or TVR were not different between the two groups, indicating that the complex revascularization techniques did not influence the clinical outcomes regarding stent implantation. An early study showed that the clinical outcomes of ostial LAD lesions were comparable with non-ostial LAD lesions in patients who received sirolimus-eluting stents (cipher stents). 11) In fact, clinical outcomes in the LM-LAD crossover stenting strategy were comparable with those in the LAD just proximal stenting strategy for the ostial pLAD-AMI patients. 9) Furthermore, unlike the two stent strategy, 24, 25) there would be no additional risk in LMT-LAD crossover stenting (± kissing balloon technique) as compared with conventional stenting.
Clinical implications of our results should be discussed. For the ostial pLAD-AMI, we did not need to hesitate to perform LM-LAD crossover stenting with/without kissing balloon technique because the stent-related outcomes, such as ST, TLR, or TVR, were not different between the ostial pLAD and non-ostial pLAD groups. Although we used IABP and catecholamine more frequently in the ostial pLAD group than in the non-ostial pLAD group, cardiac death was more frequently observed in the ostial pLAD group, partially because the baseline demographics such as number of diseased vessels, previous PCI, and MI were more serious in the ostial pLAD group. New therapeutic options except stenting or current mechanical support devices may be needed to improve the cardiac mortality of the ostial pLAD-AMI. Although the several risk scores such as the GRACE score or TIMI-risk score have been reported to be a predictor for clinical outcomes in patients with AMI, 26, 27) these classic scores were calculated by using only non-angiographic variables such as age, heart rate, blood pressure, serum creatinine, or electrocardiogram findings, partly because emergent coronary angiography was not easy to perform in the era when those risk scores were developed. However, emergent coronary angiography for AMI is widely available in the current clinical settings, especially those in Japan. Therefore, the future risk score including emergent angiographic findings may more accurately stratify AMI patients. The present study showed the greater risk of the ostial pLAD-AMI as compared with the non-ostial pLAD-AMI, which may be useful for risk stratification of AMI patients. Study Limitations: Since this study was a single center retrospective observational study, there is a risk of patient selection bias and group selection bias. In addition, the study population was relatively small, and the follow-up duration might not be sufficiently long (median 414 days [IQR 224-1209 days]) to elucidate the difference between the ostial pLAD and non-ostial pLAD groups. Furthermore, as the number of events (MACE or cardiac death) in the multivariate Cox regression analysis was relatively small, we selected independent variables that have known associations with MACE or cardiac death. We did not select independent variables that have marginal associations (P < 0.10 or P < 0.20) between the groups. Therefore, our multivariate analysis might miss true confounders. Moreover, the patients who had been treated with BMS were included in the present study, which might affect the clinical outcomes, such as TLR or TVR. Since we could not perform a statistical power analysis, there is a possibility of beta error. 28) Our results require further validation in the setting of prospective studies.
Conclusions
As compared with the non-ostial pLAD-AMI, the clinical outcomes of the ostial pLAD-AMI tended to be worse, especially cardiac death, requiring special attention to the ostial pLAD-AMI among pLAD-AMI.
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